Antitumor activity of PAbs generated by immunization with a novel HER3-targeting protein-based vaccine candidate in preclinical models

被引:1
作者
Bermudez-Abreut, Ernesto [1 ]
Baez, Gretchen Bergado [1 ]
Pestano, Melissa Martinez [1 ]
Attanasio, Giuseppe [2 ]
Castillo, Carlos Yordan Gonzales [1 ]
Fernandez, Diana Rosa Hernandez [1 ]
Alvarez-Arzola, Rydell [1 ]
Alimonti, Andrea [2 ,3 ,4 ,5 ]
Sanchez-Ramirez, Belinda [1 ]
机构
[1] Ctr Mol Immunol CIM, Immunol & Immunotherapy Div, Havana, Cuba
[2] Inst Oncol Res IOR, Dept Mol Oncol, Bellinzona, Switzerland
[3] Univ Svizzera Italiana, Fac Med, Lugano, Switzerland
[4] Univ Padua, Dept Med, Padua, Italy
[5] Oncol Inst Southern Switzerland, Med Oncol, Bellinzona, Switzerland
来源
FRONTIERS IN ONCOLOGY | 2024年 / 14卷
关键词
HER3; ErbB3; immunotherapy; cancer vaccines; PAbs; antitumor effect; CANCER; EGFR; HER3; INACTIVATION; EXPRESSION; APOPTOSIS; SURVIVAL; C-ERBB-3; RECEPTOR; GROWTH;
D O I
10.3389/fonc.2024.1472607
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Despite the cumulative evidence supporting HER3 as a target for antitumor therapies, no agents targeting HER3 have been approved for cancer treatment. Most of the agents evaluated in preclinical and clinical trials have been specific monoclonal antibodies (MAbs), with few examples of active immunotherapy directed against this receptor. However, some cancer vaccine formats may generate polyclonal antibodies (PAbs) that replicate the diverse effector mechanisms of MAbs, including ligand neutralization and receptor degradation. In this study, we developed a protein subunit-based monovalent vaccine candidate targeting the extracellular domain (ECD) of HER3. Immunization of mice with a formulation targeting murine ErbB3-ECD successfully overcome tolerance to this self-antigen, inducing high titers of ErbB3-specific PAbs. The antitumor potential of this formulation and the induced PAbs was demonstrated in vivo and in vitro in an ErbB3-overexpressing 3LL-D122-derived tumor model. The immunogenicity of the HER3-ECD-based vaccine candidate was confirmed by the induction of high titers of HER3-specific PAbs. Consistent with the initial results, HER3-ECD-targeting PAbs were cytotoxic in several human epithelial tumor cell lines and exerted antitumor effects in vivo. These results support the value of HER3 as a tumor antigen and the effector mechanisms of HER3-specific therapeutic MAbs, while suggesting the potential of the proposed vaccine candidate for the treatment of HER3-expressing carcinomas.
引用
收藏
页数:14
相关论文
共 47 条
  • [41] Seshacharyulu P., 2012, Targeting the EGFR signaling pathway in cancer therapy, V16, P15, DOI [10.1517/14728222.2011.648617, DOI 10.1517/14728222.2011.648617]
  • [42] Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549
    Sithanandam, G
    Fornwald, LW
    Fields, J
    Anderson, LM
    [J]. ONCOGENE, 2005, 24 (11) : 1847 - 1859
  • [43] Slesak B, 1998, ANTICANCER RES, V18, P2727
  • [44] Uliano J., 2023, Targeting HER3 for cancer treatment: a new horizon for an old target, V8, DOI [10.1016/j.esmoop.2023.100790, DOI 10.1016/J.ESMOOP.2023.100790]
  • [45] Cancer Immunotherapy: More Is (Much) Better
    Yarden, Yosef
    Sela, Michael
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (18) : 4030 - 4032
  • [46] Yi ES, 1997, MODERN PATHOL, V10, P142
  • [47] HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer
    Yonesaka, Kimio
    Tanizak, Junko
    Maenishi, Osamu
    Haratani, Koji
    Kawakami, Hisato
    Tanaka, Kaoru
    Hayashi, Hidetoshi
    Sakai, Kazuko
    Chiba, Yasutaka
    Tsuya, Asuka
    Goto, Hiroki
    Otsuka, Eri
    Okida, Hiroaki
    Kobayashi, Maki
    Yoshimoto, Ryoto
    Funabashi, Masanori
    Hashimoto, Yuuri
    Hirotani, Kenji
    Kagari, Takashi
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    [J]. CLINICAL CANCER RESEARCH, 2022, 28 (02) : 390 - 403